Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease

NCT05582993 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05582993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
November 6, 2024
Completion date
April 11, 2030
Enrollment
24 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd)